促黄体生成素释放激素（LHRH）激动剂ICI 118630在晚期前列腺癌治疗中的潜在疗效。

Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.

作者信息

Walker K J, Nicholson R I, Turkes A O, Turkes A, Griffiths K, Robinson M, Crispin Z, Dris S

出版信息

Lancet. 1983 Aug 20;2(8347):413-5. doi: 10.1016/s0140-6736(83)90386-0.

Abstract

8 patients with advanced prostatic carcinoma were treated with the luteinising-hormone releasing-hormone agonist, ICI 118630, for up to 3 months. Patients received subcutaneous injections of ICI 118630 (either 100 micrograms or 250 micrograms daily). At the higher dose level, plasma testosterone concentrations were significantly reduced by day 14 and approximated to those previously recorded in castrated or diethylstilboestrol-treated patients. Plasma concentrations of luteinising hormone and follicle-stimulating hormone were similarly reduced. Reduction in the dose, to 100 micrograms/day, similarly reduced plasma testosterone. ICI 118630 shows considerable potential for the management of patients with advanced carcinoma of the prostate.

摘要

8例晚期前列腺癌患者接受促黄体激素释放激素激动剂ICI 118630治疗长达3个月。患者皮下注射ICI 118630（每日100微克或250微克）。在较高剂量水平时，血浆睾酮浓度在第14天时显著降低，并接近先前在去势或己烯雌酚治疗患者中记录的水平。促黄体激素和促卵泡激素的血浆浓度也同样降低。剂量减至每日100微克时，血浆睾酮也同样降低。ICI 118630在晚期前列腺癌患者的治疗中显示出相当大的潜力。